Jawaria Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jawaria Ibrahim has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Burhan
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Shaheer Bin Shafiq
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Taha Ibrahim
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Ali Wajahat
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ammad Uddin
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ayesha Ahmed Khan
Dow University of Heath Sciences
1 shared publication
Latest Publications
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- 10 August 2026
- Published by Taylor & Francis in Seminars in Ophthalmology
- p. 1-11
Efficacy and Safety of Aceclidine in Presbyopia, a Systematic Review and Meta -Analysis
Presbyopia, an age-related oculopathy in which a decline in accommodation capabilities results in difficulties in near vision tasks and hence compromises the performance of essential activities of ...
- 10 August 2026
- Published by Taylor & Francis in Seminars in Ophthalmology
- p. 1-11
Efficacy and Safety of Aceclidine in Presbyopia, a Systematic Review and Meta -Analysis
Presbyopia, an age-related oculopathy in which a decline in accommodation capabilities results in difficulties in near vision tasks and hence compromises the performance of essential activities of ...